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Background: In the HORIZONS-AMI trial, implantation of paclitaxel-eluting stents (PES), as compared with bare-metal stents (BMS), significantly 
reduced ischemia driven repeat revascularization procedures in STEMI pts undergoing primary PCI, with similar 1-year rates of death, reinfarction 
and stent thrombosis (ST). We assessed the impact of PES versus BMS in pts with anterior myocardial infarction (MI) within a 1-year clinical follow-
up period.
Methods: Pts were randomized in a 3:1 ratio to receive PES or BMS. Compared to pts with nonanterior MI, pts with anterior MI had higher rates of 
mortality at 1 year (5.6% vs. 2.8%%, P<0.001), with comparable rates of re-MI, TVR, stroke and ST. 1315 (44%) pts had anterior MI, 977 of whom 
were randomized to PES and 338 to BMS. The occurrence of ischemia-driven TLR, TVR, MACE (death, reinfarction, ischemic TVR or stroke) and ST was 
assessed.
Results: There was no difference between PES and BMS pts with respect to diabetes, use of aspiration catheters or pre-procedure heparin, TIMI 
flow pre and post PCI, clopidogrel loading dose, and use of bivalirudin or glycoprotein IIbIIIa inhibitors. Total stent length was significantly longer with 
PES compared with BMS (median 24mm versus 20mm, P<0.001). Clinical outcomes at 12 months are shown in the Table: 
PES
n=977
BMS
n=338
P=
MACE 12.6% 14.4% 0.41
Death, all-cause 4.6% 4.8% 0.91
Cardiac death 2.9% 4.5% 0.17
Reinfarction 4.1% 5.5% 0.30
Stroke 1.3% 0.3% 0.14
TVR 6.6% 10.4% 0.02
TLR 5.1% 8.9% 0.01
Non TLR TVR 2.1% 3.1% 0.32
Stent thrombosis (def/prob) 3.3% 4.5% 0.29
Conclusions: In the prospective randomized HORIZONS-AMI trial, implantation of PES compared to BMS in pts with anterior MI resulted in a 48% 
reduction of ischemic driven TVR, with comparable rates of safety outcomes including ST.
